Skip to main content
TLX
NASDAQ Life Sciences

FDA Accepts NDA for Brain Cancer Imaging Agent TLX101-Px (Pixclara®), Sets September PDUFA Date

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.72
Mkt Cap
$3.276B
52W Low
$6.28
52W High
$20
52W Position info
71% above low
Off High info
46% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TLX sits 71% above its 52-week low of $6.28.

Summary

The FDA has accepted Telix's resubmitted New Drug Application for TLX101-Px (Pixclara®), an imaging agent for brain cancer, and set a PDUFA goal date of September 11, 2026.


Key Events · Product Development and Regulatory · TLX

  • NDA Accepted for TLX101-Px (Pixclara®)

    The FDA has accepted Telix's resubmitted New Drug Application for TLX101-Px, an investigational PET agent for imaging glioma (brain cancer).

  • PDUFA Goal Date Set

    The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for potential approval.

  • Addresses Unmet Medical Need

    TLX101-Px is intended to characterize recurrent or progressive glioma, a significant unmet medical need, and holds Orphan Drug and Fast Track designations.

  • Potential Upside to Guidance

    Telix's current FY 2026 financial guidance does not include any revenue contribution from TLX101-Px, suggesting potential upside upon approval.


Analysis · TLX · Life Sciences

The FDA's acceptance of the New Drug Application (NDA) for TLX101-Px (Pixclara®) is a significant de-risking event for Telix Pharmaceuticals. This investigational PET agent, designed for imaging glioma (brain cancer), addresses a critical unmet medical need and has previously received Orphan Drug and Fast Track designations. The assignment of a PDUFA goal date of September 11, 2026, provides a clear timeline for a potential regulatory decision, which could unlock a new revenue stream. Notably, Telix's current FY 2026 financial guidance does not factor in any revenue from TLX101-Px, indicating that a potential approval and subsequent commercialization could represent significant upside to existing expectations.

At the time of this filing, TLX was trading at $10.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $6.28 to $20.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLX - Latest Insights

TLX
Jul 21, 2026, 7:06 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $10.57
Real-time Price: $10.15 info
Change: -$0.420 (-4%) info
Market Cap: $3.428B info
TLX
Jul 20, 2026, 6:52 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $10.51
Real-time Price: $10.15 info
Change: -$0.360 (-3%) info
Market Cap: $3.428B info
TLX
Jul 16, 2026, 6:00 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $10.62
Real-time Price: $10.15 info
Change: -$0.470 (-4%) info
Market Cap: $3.428B info
TLX
Jul 15, 2026, 8:30 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $11.29
Real-time Price: $10.15 info
Change: -$1.14 (-10%) info
Market Cap: $3.428B info
TLX
Jul 02, 2026, 4:27 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $11.87
Real-time Price: $10.15 info
Change: -$1.72 (-14%) info
Market Cap: $3.428B info